Outsourcing pharmacovigilance activities is a standard business practice in a continuously expanding market segment. In the past, outsourced safety services were limited due to con¬cerns about confidentiality, data security, and liability in cases of regulatory non-compliance, which are all still important considerations today. Because of the changing technology and regulatory environments, sponsors are reevaluating the advantages and disadvantages of out¬sourcing their pharmacovigilance obligations.
Pharmacovigilance & Patient Safety
Clinical trial participants help us speed breakthroughs in modern drug development. Our job is to protect them.
PRA Health Sciences To Report Fourth Quarter 2014 Earnings
PRA Health Sciences, Inc. (NASDAQ: PRAH) will release its fourth quarter and year end 2014 results after the market closes on Wednesday, February 18,…
PRA Leads Novel Multiple Myeloma Drug Development
PRA Health Sciences supported 2 multiple myeloma clinical trials, a Phase III and a “rollover,” for a large biotech client. This management contract…